Evidence map›Paper›PMID 39392236›Full record

ReviewAmerican journal of reproductive immunology (New York, N.Y. : 1989)2024

COVID-19 Vaccine mRNA Biodistribution: Maternal and Fetal Exposure Risks.

Connie Zhong, Koral Cohen, Xinhua Lin, Emily Schiller, Surendra Sharma, Nazeeh Hanna

Abstract readReview
In one paragraph

Review in American journal of reproductive immunology (New York, N.Y. : 1989), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Connie ZhongNew York University-Grossman Long Island School of Medicine, Mineola, New York, USA.
Koral CohenNew York University-Grossman Long Island School of Medicine, Mineola, New York, USA.
Xinhua LinWomen and Children's Research Laboratory, Departments of Foundations of Medicine, New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.
Emily SchillerNew York University-Grossman Long Island School of Medicine, Mineola, New York, USA.
Surendra SharmaDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0002-4331-3467
Nazeeh HannaWomen and Children's Research Laboratory, Departments of Foundations of Medicine, New York University-Grossman Long Island School of Medicine, Mineola, New York, USA.ORCID 0000-0003-2167-5712

Funding

Immune activating syncytiotrophoblast microvesicles and danger associated molecular patterns in preeclampsia riskR01AI141501 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SHARMA, SURENDRA · 2019 to 2023
$2.8M
Placenta-specific miR-519c-mediated induction of immune tolerance in human placentaR01HD098258 · NICHD · NYU LONG ISLAND SCHOOL OF MEDICINE · PI HANNA, NAZEEH N · 2020 to 2024
$1.8M
Targeting proteinopathy/tauopathy and impaired autophagy for mechanistic understanding and therapeutic intervention of preeclampsiaR01HD110408 · NICHD · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SURENDRA SHARMA · 2024 to 2026
$1.4M
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNICHD NIH HHS 1R01HD098258NICHD NIH HHS R01AI141501NICHD NIH HHS R01 HD098258NICHD NIH HHS R01HD110408
6 · The paper itself

Abstract

SARS-CoV-2 infection during pregnancy has severe consequences on maternal and neonatal health. Presently, vaccination stands as a critical preventive measure for mitigating infection-related risks. Although the initial clinical trials for the COVID-19 vaccines excluded pregnant women, subsequent investigations have indicated mRNA vaccinations' effectiveness and short-term safety during pregnancy. However, there is a lack of information regarding the potential biodistribution of the vaccine mRNA during pregnancy and lactation. Recent findings indicate that COVID-19 vaccine mRNA has been detected in breast milk, suggesting that its presence is not confined to the injection site and raises the possibility of similar distribution to the placenta and the fetus. Furthermore, the potential effects and responses of the placenta and fetus to the vaccine mRNA are still unknown. While potential risks might exist with the exposure of the placenta and fetus to the COVID-19 mRNA vaccine, the application of mRNA therapies for maternal and fetal conditions offers a groundbreaking prospect. Future research should leverage the unique opportunity provided by the first-ever application of mRNA vaccines in humans to understand their biodistribution and impact on the placenta and fetus in pregnant women. Such insights could substantially advance the development of safer and more effective future mRNA-based therapies during pregnancy.

Indexed as

COVID-19COVID-19 VaccinesFetusPlacentaPregnancy Complications, InfectiousSARS-CoV-2FemaleHumansMilk, HumanmRNA VaccinesPregnancyRNA, MessengerTissue DistributionVaccinationVaccines, SyntheticCOVID-19 VaccinesmRNA VaccinesRNA, MessengerVaccines, SyntheticbiodistributionCOVID‐19lipid nanoparticlesneonateplacentapregnancyvaccine mRNA

Identifiers

PMID39392236
PMCPMC13325971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.